Physician profile
Hyung Cho
NPI 1265737415
$20,955.63
in general payments reported to CMS, 2019-2025
22 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,307 · 2020: $1,265 · 2021: $3,858 · 2022: $5,299 · 2023: $1,919 · 2024: $1,887 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $5,723.34 | 2019-2022 | |
| Alimera Sciences, INC. | $5,130.48 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $2,838.90 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Regeneron Healthcare Solutions, INC. | $2,726.25 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $715.51 | 2023-2025 | Izervay |
| Notal Vision, INC. | $679.17 | 2022 | |
| Allergan, INC. | $562.85 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $491.83 | 2023-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $437.09 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Novartis Pharmaceuticals Corporation | $292.51 | 2019-2021 | |
| Alcon Vision LLC | $265.38 | 2021 | |
| Abbvie INC. | $262.90 | 2022-2025 | Ozurdex |
| Bausch & Lomb Americas INC. | $212.95 | 2024-2025 | Xipere, Visudyne |
| Regeneron Pharmaceuticals, INC. | $123.27 | 2022 | |
| Pfizer INC. | $111.97 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $102.47 | 2019-2022 | |
| Coherus Oncology, INC. | $82.67 | 2022-2023 | |
| Mallinckrodt Enterprises LLC | $70.44 | 2019 | |
| New World Medical,INC. | $46.19 | 2019 | |
| Sandoz INC. | $38.39 | 2024 | Cimerli |
| Halozyme INC | $24.74 | 2024 | Hylenex Recombinant |
| Dutch Ophthalmic, USA | $16.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$87,506.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyung Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.